...
首页> 外文期刊>European respiratory review >Asthma-COPD overlap: current understanding and the utility of experimental models
【24h】

Asthma-COPD overlap: current understanding and the utility of experimental models

机译:哮喘 - COPD重叠:目前的理解和实验模型的效用

获取原文

摘要

Pathological features of both asthma and COPD coexist in some patients and this is termed asthma-COPD overlap (ACO). ACO is heterogeneous and patients exhibit various combinations of asthma and COPD features, making it difficult to characterise the underlying pathogenic mechanisms. There are no controlled studies that define effective therapies for ACO, which arises from the lack of international consensus on the definition and diagnostic criteria for ACO, as well as scant in vitro and in vivo data. There remain unmet needs for experimental models of ACO that accurately recapitulate the hallmark features of ACO in patients. The development and interrogation of such models will identify underlying disease-causing mechanisms, as well as enabling the identification of novel therapeutic targets and providing a platform for assessing new ACO therapies. Here, we review the current understanding of the clinical features of ACO and highlight the approaches that are best suited for developing representative experimental models of ACO.
机译:一些患者哮喘和COPD共存的病理特征,这是称哮喘 - COPD重叠(ACO)。 ACO是异质的,患者表现出各种组合的哮喘和COPD特征,使得难以表征潜在的致病机制。没有对ACO的有效疗法定义有效疗法的受控研究,这源于缺乏关于ACO的定义和诊断标准的国际共识,以及体外和体内数据的狭窄。 ACO的实验模型仍然存在未满足的需求,可准确地重新承载患者ACO的标志特征。这些模型的开发和审讯将识别潜在的疾病导致机制,并能够识别新的治疗目标并提供用于评估新的ACO疗法的平台。在这里,我们审查了目前对ACO临床特征的理解,并突出了最适合发展ACO的代表实验模型的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号